http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019073331-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cdd6c9aa2a56078633fd99c1537ae
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2813
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035
filingDate 2018-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31439443e037e3ddd3ad3736194a7d61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_139c999fade8264a2764edacf5b52c0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fb9e8874b4b9861b0cd277f84ddfa91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e5bd2a387a0efdb57939ab181bd40fd
publicationDate 2019-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2019073331-A3
titleOfInvention Pharmaceutical compositions of apremilast
abstract The present invention relates to a disintegrant free pharmaceutical composition comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. Particularly the present invention relates to disintegrant free immediate release dosage form comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. It further relates to process of preparing such composition and its use in psoriatic arthritis and psoriasis.
priorityDate 2017-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013045961-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014370092-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012171288-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11561674
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496369

Total number of triples: 30.